Literature DB >> 26792584

A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.

Colin H Ridyard1, Dalia M M Dawoud2, Lorna V Tuersley1, Dyfrig A Hughes3.   

Abstract

BACKGROUND: Subcutaneous injections allow for self-administration, but consideration of patients' perspectives on treatment choice is important to ensure adherence. Previous systematic reviews have been limited in their scope for assessing preferences in relation to other routes of administration.
OBJECTIVE: Our objective was to examine patients' perspectives on subcutaneously administered self-injectable medications when compared with other routes or methods of administration for the same medicines.
METHODS: Nine electronic databases were searched for publications since 2000 using terms pertaining to methods of administration, choice behavior, and adverse effects. Eligibility for inclusion was determined through reference to specific criteria by two independent reviewers. Results were described narratively.
RESULTS: Of the 1726 papers screened, 85 met the inclusion criteria. Studies were focused mainly on methods of insulin administration for diabetes but also included treatments for pediatric growth disorders, multiple sclerosis, HIV, and migraine. Pen devices and autoinjectors were favored over administration with needle and syringe, particularly with respect to ergonomics, convenience, and portability. Inhalation appeared to be more acceptable than subcutaneous injection (in the case of insulin), but how subcutaneous infusion, intramuscular injection, and needle-free injection devices compare with subcutaneous injections in terms of patient preference is less certain.
CONCLUSIONS: The review identified a number of studies showing the importance of the methods and routes of drug delivery on patient choice. However, studies were prone to bias, and further robust evidence based on methodologically sound approaches is required to demonstrate how patient choice might translate to improved adherence.

Entities:  

Mesh:

Year:  2016        PMID: 26792584     DOI: 10.1007/s40271-015-0160-x

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  92 in total

1.  Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine.

Authors:  Irving Gottesman; Patrice Perron; Lori Berard; John Stewart; Nils Basso; Kim Mettimano; Thomas Elliott
Journal:  Diabetes Technol Ther       Date:  2012-07-09       Impact factor: 6.118

2.  Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.

Authors:  Aaron P Turner; Rhonda M Williams; Alicia P Sloan; Jodie K Haselkorn
Journal:  Rehabil Psychol       Date:  2009-02

3.  Comparison of intuitiveness, ease of use, and preference in two insulin pens.

Authors:  Toshinari Asakura; Klaus H Jensen
Journal:  J Diabetes Sci Technol       Date:  2009-03-01

4.  Continuous subcutaneous insulin infusion therapy: effects on quality of life.

Authors:  Ursina Scheidegger; Sabin Allemann; Karl Scheidegger; Peter Diem
Journal:  Swiss Med Wkly       Date:  2007-08-25       Impact factor: 2.193

Review 5.  Effect of medication dosing frequency on adherence in chronic diseases.

Authors:  Sameer D Saini; Philip Schoenfeld; Kellee Kaulback; Marla C Dubinsky
Journal:  Am J Manag Care       Date:  2009-06-01       Impact factor: 2.229

6.  Patient satisfaction and clinical outcome after injecting gonadotropins with use of a needle-free carbon dioxide injection system for controlled ovarian hyperstimulation for in vitro fertilization.

Authors:  Amy Solnica; Cheongeun Oh; Michael M Cho; Jacquelyn S Loughlin; David H McCulloh; Peter G McGovern
Journal:  Fertil Steril       Date:  2009-04-07       Impact factor: 7.329

7.  Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.

Authors:  Alessandra Lugaresi; Valentina Durastanti; Claudio Gasperini; Marina Lai; Carlo Pozzilli; Giuseppe Orefice; Stefano Sotgiu; Emilio Pucci; Bruno Ardito; Enrico Millefiorini
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

8.  An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).

Authors:  Jacob P Lalezari; Michael Saag; Charles Walworth; Peter Larson
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

9.  Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.

Authors:  Thomas Haak; Steven Edelman; Claudia Walter; Brigitte Lecointre; Gerry Spollett
Journal:  Clin Ther       Date:  2007-04       Impact factor: 3.393

Review 10.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

Authors:  Kathleen Costello; Patricia Kennedy; Jo Scanzillo
Journal:  Medscape J Med       Date:  2008-09-30
View more
  9 in total

Review 1.  Methods to Summarize Discrete-Choice Experiments in a Systematic Review: A Scoping Review.

Authors:  Daksh Choudhary; Megan Thomas; Kevin Pacheco-Barrios; Yuan Zhang; Pablo Alonso-Coello; Holger Schünemann; Glen Hazlewood
Journal:  Patient       Date:  2022-07-13       Impact factor: 3.481

2.  Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus.

Authors:  Ebony Dashiell-Aje; Gale Harding; Katie Pascoe; Jane DeVries; Pamela Berry; Sulabha Ramachandran
Journal:  Patient       Date:  2018-02       Impact factor: 3.883

Review 3.  Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.

Authors:  Franck Boccara; Ricardo Dent; Luis Ruilope; Paul Valensi
Journal:  Adv Ther       Date:  2017-07-17       Impact factor: 3.845

4.  Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study.

Authors:  Pierachille Santus; Matteo Ferrando; Ilaria Baiardini; Dejan Radovanovic; Alice Fattori; Fulvio Braido
Journal:  World Allergy Organ J       Date:  2019-04-28       Impact factor: 4.084

Review 5.  Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review.

Authors:  Hiba El Masri; Treasure M McGuire; Mieke L van Driel; Helen Benham; Samantha A Hollingworth
Journal:  Patient Prefer Adherence       Date:  2022-09-20       Impact factor: 2.314

6.  Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome.

Authors:  Christopher V Almario; Samuel Eberlein; Carine Khalil; Brennan M R Spiegel
Journal:  Neurogastroenterol Motil       Date:  2021-04-02       Impact factor: 3.598

7.  Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris®) in Pituitary-Suppressed Healthy Women.

Authors:  Wilhelmina Bagchus; Özkan Yalkinoglu; Peter Wolna
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-11       Impact factor: 5.555

8.  Patients' preferences for headache acute and preventive treatment.

Authors:  Dimos D Mitsikostas; Ioanna Belesioti; Chryssa Arvaniti; Euthymia Mitropoulou; Christina Deligianni; Elina Kasioti; Theodoros Constantinidis; Manolis Dermitzakis; Michail Vikelis
Journal:  J Headache Pain       Date:  2017-10-06       Impact factor: 7.277

9.  Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.

Authors:  Séverine Vermeire; François D'heygere; Antoine Nakad; Denis Franchimont; Fernand Fontaine; Edouard Louis; Philippe Van Hootegem; Olivier Dewit; Guy Lambrecht; Beatrijs Strubbe; Filip Baert
Journal:  Patient Prefer Adherence       Date:  2018-07-06       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.